Regular Use of VKA Prior to COVID-19 Associated with Lower 7-Day Survival in Hospitalized Frail Elderly COVID-19 Patients: The GERIA-COVID Cohort Study.
Age Factors
Aged, 80 and over
Anticoagulants
/ administration & dosage
COVID-19
/ blood
Disease-Free Survival
Female
Frail Elderly
Humans
Longitudinal Studies
Male
Risk Factors
SARS-CoV-2
/ metabolism
Severity of Illness Index
Sex Factors
Survival Rate
Vitamin K
/ antagonists & inhibitors
COVID-19 Drug Treatment
COVID-19
SARS-CoV-2
anticoagulation
older adults
survival
vitamin K antagonist
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
24 Dec 2020
24 Dec 2020
Historique:
received:
26
11
2020
revised:
20
12
2020
accepted:
22
12
2020
entrez:
30
12
2020
pubmed:
31
12
2020
medline:
13
1
2021
Statut:
epublish
Résumé
Vitamin K concentrations are inversely associated with the clinical severity of COVID-19. The objective of this cohort study was to determine whether the regular use of vitamin K antagonist (VKA) prior to COVID-19 was associated with short-term mortality in frail older adults hospitalized for COVID-19. Eighty-two patients consecutively hospitalized for COVID-19 in a geriatric acute care unit were included. The association of the regular use of VKA prior to COVID-19 with survival after 7 days of COVID-19 was examined using a propensity-score-weighted Cox proportional-hazards model accounting for age, sex, severe undernutrition, diabetes mellitus, hypertension, prior myocardial infarction, congestive heart failure, prior stroke and/or transient ischemic attack, CHA2DS2-VASc score, HAS-BLED score, and eGFR. Among 82 patients (mean ± SD age 88.8 ± 4.5 years; 48% women), 73 survived COVID-19 at day 7 while 9 died. There was no between-group difference at baseline, despite a trend for more frequent use of VKA in those who did not survive on day 7 (33.3% versus 8.2%, Regular use of VKA was associated with increased mortality at day 7 in hospitalized frail elderly patients with COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Vitamin K concentrations are inversely associated with the clinical severity of COVID-19. The objective of this cohort study was to determine whether the regular use of vitamin K antagonist (VKA) prior to COVID-19 was associated with short-term mortality in frail older adults hospitalized for COVID-19.
METHODS
METHODS
Eighty-two patients consecutively hospitalized for COVID-19 in a geriatric acute care unit were included. The association of the regular use of VKA prior to COVID-19 with survival after 7 days of COVID-19 was examined using a propensity-score-weighted Cox proportional-hazards model accounting for age, sex, severe undernutrition, diabetes mellitus, hypertension, prior myocardial infarction, congestive heart failure, prior stroke and/or transient ischemic attack, CHA2DS2-VASc score, HAS-BLED score, and eGFR.
RESULTS
RESULTS
Among 82 patients (mean ± SD age 88.8 ± 4.5 years; 48% women), 73 survived COVID-19 at day 7 while 9 died. There was no between-group difference at baseline, despite a trend for more frequent use of VKA in those who did not survive on day 7 (33.3% versus 8.2%,
CONCLUSIONS
CONCLUSIONS
Regular use of VKA was associated with increased mortality at day 7 in hospitalized frail elderly patients with COVID-19.
Identifiants
pubmed: 33374341
pii: nu13010039
doi: 10.3390/nu13010039
pmc: PMC7824717
pii:
doi:
Substances chimiques
Anticoagulants
0
Vitamin K
12001-79-5
Types de publication
Clinical Trial
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Références
Crit Rev Oncol Hematol. 2013 Dec;88(3):637-54
pubmed: 23958677
Am J Respir Cell Mol Biol. 2007 Sep;37(3):309-21
pubmed: 17496152
Blood. 2020 Jul 2;136(1):144-147
pubmed: 32462179
Blood. 2007 Apr 1;109(7):2823-31
pubmed: 17138823
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Am J Respir Crit Care Med. 2012 Nov 1;186(9):866-76
pubmed: 22936357
J Cell Mol Med. 2016 Nov;20(11):2029-2035
pubmed: 27295971
Scand J Clin Lab Invest. 2020 Nov;80(7):525-527
pubmed: 32779537
Crit Care. 2020 Sep 16;24(1):559
pubmed: 32938471
Am J Kidney Dis. 2012 Feb;59(2):186-95
pubmed: 22169620
Chest. 2008 Jun;133(6 Suppl):160S-198S
pubmed: 18574265
Cardiovasc Drugs Ther. 2020 Oct 19;:
pubmed: 33074525
Transplantation. 2020 Nov;104(11):e329-e331
pubmed: 33122591
J Biol Chem. 1988 Aug 15;263(23):11033-6
pubmed: 3042764
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
Adv Exp Med Biol. 1974;48(0):185-209
pubmed: 4372871
N Engl J Med. 2018 May 03;378(18):1704-1714
pubmed: 29719190
J Am Coll Cardiol. 2020 Oct 20;76(16):1815-1826
pubmed: 32860872
J Nutr. 2003 Aug;133(8):2565-9
pubmed: 12888638
Blood Rev. 2012 Jul;26(4):155-66
pubmed: 22520397
Clin Infect Dis. 2020 Aug 27;:
pubmed: 32852539
Circulation. 2004 Nov 30;110(22):3480-7
pubmed: 15545515
J Thromb Haemost. 2016 Aug;14(8):1588-99
pubmed: 27172994
Eur Heart J. 2010 Oct;31(19):2369-429
pubmed: 20802247
Soins Gerontol. 1998 Jun;(13):23-7
pubmed: 9735854
J Nutr. 2001 Nov;131(11):2910-5
pubmed: 11694617
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112